- Conditions
- Diarrhea
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- South Miami, Florida • Houston, Texas • La Porte, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 79
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatic Encephalopathy
- Interventions
- Rifaximin, placebo
- Drug
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
- Interventions
- Rifaximin, Glucose and lactulose hydrogen breath testing
- Drug · Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Parkinson's Disease, Small Intestinal Bacterial Overgrowth
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Chronic Kidney Disease
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- Jason Stubbs, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Rosacea
- Interventions
- Rifaximin (XIFAXAN), Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Best Practice, Questionnaire Administration, Rifaximin
- Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Crohn's Disease
- Interventions
- Rifaximin EIR, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 72
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Malignancy, Bone Marrow Transplantation
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Overt Hepatic Encephalopathy
- Interventions
- 40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 34
- States / cities
- Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Liver Cirrhosis, Chronic Hepatitis C
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- David E. Kaplan, MD MSc
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- open-label rifaximin, double-blind placebo, double-blind rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 293
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more
- Conditions
- Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
- Interventions
- Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
- Drug · Device · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Sickle Cell Disease
- Interventions
- Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Orange, California • Denver, Colorado • Atlanta, Georgia + 2 more
- Conditions
- IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy, Light Chain Deposition Disease, Monoclonal Gammopathy, Smoldering Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia, Gammopathy, Monoclonal, Gammopathy Igg
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Papulopustular Rosacea
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 38
- States / cities
- Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more
- Conditions
- Dysentery, Diarrhea, Enteric Campylobacteriosis
- Interventions
- Rifaximin intervention, Placebo intervention
- Biological
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Severe Hepatic Impairment
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Liver Cirrhosis
- Interventions
- Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Rifaximin, N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Liver Cirrhosis, Renal Failure
- Interventions
- Rifaximin, Lactulose
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatic Encephalopathy
- Interventions
- Rifaximin SSD, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 90
- States / cities
- Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more
- Conditions
- Chronic Abdominal Pain, Small Intestinal Bacterial Overgrowth
- Interventions
- Lactulose Breath Test, xifaxan, placebo
- Procedure · Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
- Interventions
- Placebo, Rifaximin
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 35 Years to 72 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah